Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
June 09, 2016 10:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress...
Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
June 03, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
May 31, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Study Successfully Identified Effective and Well-tolerated Dose for Registration StudiesPhase 3 Clinical Program Planned NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding...
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
May 26, 2016 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
May 19, 2016 06:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Conference Call and Webcast Today at 8:00 a.m. ETSuccessfully-executed Dose-finding Study Identified 5.6 mg as the Efficacious and Well-tolerated Dose for Registration StudiesPlan to Meet with the...
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
May 09, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nervous...
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
May 02, 2016 07:05 ET
|
Tonix Pharmaceuticals Holding Corp.
- Top-line Results on Track to be Reported 3Q 2016 for Pivotal Study in Flagship Program - NEW YORK, May 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix),...
Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
March 29, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 29, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
March 09, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
- TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for bedtime administration currently under development for the long-term management of fibromyalgia and treatment of...
Tonix Pharmaceuticals to Present at the 28th Annual ROTH Conference
March 08, 2016 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 08, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...